Stocks
Atrium Therapeutics, Inc.RNA
NASDAQHealthcareBiotechnology$8.20
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing RNA-based therapies for rare and prevalent diseases. Its lead programs target genetic drivers of disease with potential for disease modification. Investors track the company for its pipeline progress and platform versatility in nucleic acid therapeutics.
52W Range: $7.49-$16.77
Congressional Interest in Atrium Therapeutics, Inc. (RNA)
No congressional trades have been disclosed for Atrium Therapeutics, Inc. (RNA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading RNA?
No congressional trades found for this stock.